Artelo Biosciences, INC S-1 registration statements

Artelo Biosciences, Inc. has filed a Form S-1 registration statement to allow for the resale of up to 9,820,294 shares of common stock by certain selling stockholders.

Artelo Biosciences files an S-1 registration statement for the resale of up to 4.27 million common shares by Square Gate Capital, potentially accessing up to $50 million in future equity financing.

Artelo Biosciences, a clinical-stage biopharmaceutical company, is conducting a best-efforts public offering to raise up to $10.9 million while addressing Nasdaq listing compliance issues and reporting positive interim clinical trial data.

Artelo Biosciences files an S-1/A for a best efforts public offering of up to 1.64M shares and warrants to raise capital and address a Nasdaq listing deficiency.

Artelo Biosciences, a clinical-stage biopharmaceutical company, is offering up to 1.64 million shares and pre-funded warrants to raise capital, primarily for working capital and to address Nasdaq listing deficiencies.

Artelo Biosciences filed an S-1 registration statement for the resale of up to 899,972 shares by securityholders, highlighting both promising clinical trial results and significant financial challenges, including a going concern doubt.

Artelo Biosciences, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 920,092 shares of common stock and warrants by selling securityholders, while simultaneously disclosing substantial doubt about its ability to continue as a going concern and non-compliance with Nasdaq's minimum stockholders' equity requirement.